FiercePharma, by Eric Sagonowsky, Apr 10, 2019 For years, drugmakers and PBMs have tussled over who’s to blame for high drug prices. That didn’t change Tuesday when a congressional committee hauled in executives from insulin makers Sanofi, Eli Lilly and Novo Nordisk as well as from pharmacy benefit managers CVS, Express Scripts and Optum. Going […]
FiercePharma, by Carly Helfand, Jan 28, 2019 AstraZeneca has struck a deal with UPMC Health Plan (USA) that links reimbursement for the blood thinner, which is approved to cut the risk of death or a second heart attack in people who have already had one, to patients’ cardiovascular outcomes—the usual trade-off for a value-based deal. But […]
FiercePharma, by Arlene Weintraub, Jan 29, 2019 When Dave Lennon, president of Novartis unit AveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 million to $5 million, some pricing critics immediately raised red flags. But then the Institute for Clinical […]
Reuters, Andrew Chung, Jun 12, 2017 The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9-0 […]
FiercePharma, by Tracy Staton on May 3, 2017 Years ago, after a series of high-profile scandals, teaching hospitals around the country started raising hurdles to pharma reps. Some outright barred salespeople at the door. Others just required appointments. However they managed it, they apparently changed prescribing habits, too. That’s the conclusion of a new study, […]
FiercePharma / by Eric Sagonowsky onMay 3, 2017 On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a patient on Repatha has a heart attack or stroke, the drugmaker will provide a full refund. As the […]
by Evan Sweeney on Apr 14, 2017 in FierceHealthcare Healthcare providers and digital health companies are searching desperately for ways to get patients more engaged in their care. Doing so may require some radical changes to care delivery. As smartphones and mobile devices have become more ingrained in everyday life, many view technology as the […]
10. Aug. 2016, FiercePharma, Tracy Staton Copay discount programsbecome popular among biosimilar manufacturers to boost the adoption of their products. These copay assistence programs can come in form of upfront out-of-pocket financial support (e.g. Sun Pharmaceuticals for their Gleevec-alike imatinib mesylate) or the reduction of upfront cost to the patients (e.g. the cost of the […]
February 25, 2016 | By Tracy Staton in FiercePharma In an article in Science Translational Medicine, researchers from the Massachusetts Institute of Technology, Dana-Farber Cancer Institute and the Broad Institute say patient loans could be designed to link payment to the clinical benefits of their treatment. In a way, they would be pay-for-performance deals–an idea […]
HIKMA filling the gaps when bigger operators have plant problems and drug shortages arise FiercePharma Manufacturing, 13. March 2014 By Eric Palmer Middle East-based Hikma Pharmaceuticals is not a large pharma player. The drugmaker’s $1.365 billion in 2013 revenues is about what a Big Pharma company would report for sales of one drug. But it […]